REGENXBIO Inc. (RGNX) Current Ratio
- Current ratio · latest quarter: Value 2.86×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.86× | Current assets / current liabilities. $236.16M ÷ $82.62M ≈ 2.86× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 236.16M USD | Assets, Current |
| Current obligations | 82.62M USD | Liabilities, Current |
| Cash and equivalents | 36.49M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 69.03M USD | Marketable Securities, Current |
| Customer receivables | 106.75M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 15.55M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $236.16M | $82.62M | $36.49M | $69.03M | $106.75M | (m) | $15.55M | (m) | 2.86× |
| 2026-03-31 | $186.52M | $71.11M | $15.23M | $135.26M | $10.04M | (m) | $21.21M | (m) | 2.62× |
| 2025-12-31 | $281.28M | $118.09M | $34.47M | $195.60M | $26.38M | (m) | $21.36M | (m) | 2.38× |
| 2025-09-30 | $331.97M | $124.57M | $58.80M | $215.40M | $25.35M | (m) | $22.27M | (m) | 2.66× |
| 2025-06-30 | $373.75M | $119.54M | $79.56M | $243.74M | $20.20M | (m) | $21.66M | (m) | 3.13× |
| 2025-03-31 | $313.24M | $106.73M | $130.10M | $137.76M | $18.19M | (m) | $19.04M | (m) | 2.93× |
| 2024-12-31 | $278.00M | $103.19M | $57.53M | $177.16M | $20.47M | (m) | $22.80M | (m) | 2.69× |
| 2024-09-30 | $313.40M | $102.72M | $56.62M | $198.84M | $23.60M | (m) | $19.52M | (m) | 3.05× |
| 2024-06-30 | $346.68M | $98.27M | $57.77M | $232.59M | $22.81M | (m) | $16.36M | (m) | 3.53× |
| 2024-03-31 | $395.42M | $110.18M | $112.97M | $225.73M | $15.83M | (m) | $31.36M | (m) | 3.59× |
| 2023-12-31 | $334.97M | $130.27M | $34.52M | $240.74M | $24.79M | (m) | $22.79M | (m) | 2.57× |
| 2023-09-30 | $365.84M | $127.35M | $53.05M | $248.84M | $28.04M | (m) | $21.86M | (m) | 2.87× |
| 2023-06-30 | $378.81M | $117.89M | $68.60M | $251.48M | $21.38M | (m) | $11.64M | (m) | 3.21× |
| 2023-03-31 | $389.20M | $112.33M | $70.09M | $261.73M | $18.86M | (m) | $23.28M | (m) | 3.46× |
| 2022-12-31 | $415.98M | $130.43M | $96.95M | $267.69M | $28.08M | (m) | $27.21M | (m) | 3.19× |
| 2022-09-30 | $436.64M | $123.55M | $118.54M | $263.87M | $32.55M | (m) | $25.21M | (m) | 3.53× |
| 2022-06-30 | $465.42M | $114.56M | $121.37M | $281.59M | $37.50M | (m) | $16.98M | (m) | 4.06× |
| 2022-03-31 | $446.88M | $119.94M | $191.87M | $202.26M | $27.02M | (m) | $24.71M | (m) | 3.73× |
| 2021-12-31 | $518.83M | $130.47M | $345.21M | $112.23M | $32.44M | (m) | $11.39M | (m) | 3.98× |
| 2021-09-30 | $410.16M | $106.77M | $228.39M | $111.47M | $46.02M | (m) | $19.84M | (m) | 3.84× |
| 2021-06-30 | $437.39M | $91.55M | $257.07M | $117.67M | $44.39M | (m) | $9.35M | (m) | 4.78× |
| 2021-03-31 | $498.64M | $83.96M | $291.48M | $149.40M | $41.04M | (m) | $11.31M | (m) | 5.94× |
| 2020-12-31 | $531.20M | $81.45M | $338.43M | $137.31M | $43.00M | (m) | $10.62M | (m) | 6.52× |
| 2020-09-30 | $386.95M | $63.61M | $93.22M | $148.31M | $122.12M | (m) | $15.24M | (m) | 6.08× |
| 2020-06-30 | $329.08M | $40.20M | $94.22M | $174.96M | (m) | (m) | $10.90M | (m) | 8.19× |
| 2020-03-31 | $338.23M | $31.79M | $69.41M | $209.85M | (m) | (m) | $9.01M | (m) | 10.64× |
| 2019-12-31 | $345.03M | $33.68M | $69.51M | $226.70M | $38.15M | (m) | $6.41M | (m) | 10.25× |
| 2019-09-30 | $360.23M | $31.34M | $79.59M | $252.13M | (m) | (m) | $9.61M | (m) | 11.49× |
| 2019-06-30 | $359.49M | $24.66M | $55.14M | $286.35M | (m) | (m) | $5.85M | (m) | 14.58× |
| 2019-03-31 | $303.88M | $21.39M | $55.85M | $229.37M | (m) | (m) | $4.20M | (m) | 14.21× |
| 2018-12-31 | $337.91M | $22.18M | $75.56M | $244.20M | (m) | (m) | $4.41M | (m) | 15.24× |
| 2018-09-30 | $386.36M | $19.12M | $142.42M | $230.17M | (m) | (m) | $5.21M | (m) | 20.21× |
| 2018-06-30 | $293.27M | $16.85M | $106.89M | $179.60M | (m) | (m) | $4.23M | (m) | 17.40× |
| 2018-03-31 | $262.72M | $14.88M | $71.87M | $158.00M | (m) | (m) | $5.01M | (m) | 17.66× |
| 2017-12-31 | $168.00M | $14.44M | $46.66M | $114.12M | (m) | (m) | $4.83M | (m) | 11.64× |
| 2017-09-30 | $172.16M | $13.40M | $59.88M | $106.78M | (m) | (m) | $2.59M | (m) | 12.85× |
| 2017-06-30 | $165.82M | $11.46M | $57.65M | $104.43M | (m) | (m) | $3.95M | (m) | 14.47× |
| 2017-03-31 | $148.80M | $9.96M | $82.05M | $63.76M | (m) | (m) | $4.13M | (m) | 14.94× |
| 2016-12-31 | $93.37M | $9.67M | $24.84M | $64.71M | (m) | (m) | $1.54M | (m) | 9.66× |
| 2016-09-30 | $96.62M | $14.38M | $28.11M | $63.66M | (m) | (m) | $5.38M | (m) | 6.72× |
| 2016-06-30 | $97.91M | $9.15M | $30.08M | $64.12M | (m) | (m) | $2.08M | (m) | 10.70× |
| 2016-03-31 | $105.58M | $5.78M | $35.51M | $65.54M | (m) | (m) | $1.11M | (m) | 18.26× |
| 2015-12-31 | $118.15M | $4.34M | $54.12M | $60.02M | (m) | (m) | $1.01M | (m) | 27.23× |
| 2015-09-30 | $215.49M | $5.31M | $205.32M | $8.03M | (m) | (m) | $3.10M | (m) | 40.60× |
| 2014-12-31 | $3.03M | $9.19M | $1.12M | (m) | $805.00K | (m) | $334.00K | (m) | 0.33× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |